To report the long-term outcomes of a pediatric patient with recurrent Wilms tumor treated with BRAF/MEK inhibition, focusing on the implications of targeted therapy.
Key Findings:
The patient remains disease-free two years after discontinuation of targeted therapy, marking a significant milestone in treatment outcomes.
Targeted therapy was well tolerated with only minor adverse effects, indicating a favorable safety profile.
This case represents the first report of long-term survival after targeted therapy for multiply relapsed BRAF V600E Wilms tumor, suggesting potential for broader application.
Interpretation:
The successful use of precision-targeted therapy in this case suggests potential for broader application in similar cases of relapsed Wilms tumor.
Limitations:
This is a single case report, limiting generalizability and necessitating further studies.
Long-term effects of BRAF/MEK inhibition in pediatric patients remain unclear, highlighting the need for more extensive research.
Conclusion:
Targeted therapy with BRAF/MEK inhibitors may offer a promising treatment avenue for recurrent Wilms tumor, warranting further investigation.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
